Page 178 - AI for Good Innovate for Impact

AI for Good Innovate for Impact

Use Case 26: AI-Enhanced Organoid Platform for Pandemic

Preparedness and Personalized Medicine

Country: China, Hong Kong SAR
Organization:Cooperative Open Intelligent Computing Industry Alliance (Collaborating with
C2itech Limited)

Contact person: Alex Li alex.li@ c2itech .HK. Phone: +852 98765443 (WhatsApp)

1 Use Case Summary Table

Category Healthcare
Problem addressed The Artificial Intelligence (AI)-Enhanced Organoid Platform aims to
revolutionize pandemic preparedness and personalized medicine by
leveraging cutting-edge AI technologies. It integrates 3D organoid
models with deep learning algorithms to simulate human respiratory
tract responses, predict viral mutations, and optimize drug discovery
processes.

Solution to the prob- Inefficient Drug Screening: Traditional methods for respiratory virus
lem drug testing are slow and costly, delaying critical treatments during
outbreaks.
Unpredictable Viral Evolution: Current tools cannot accurately forecast
high-risk viral variants, hindering proactive vaccine development.
Limited Access to Personalized Medicine: Developing regions lack
affordable, tailored treatments for respiratory diseases.

Technology keywords Deep learning models, Generative AI, AI-powered image analysis

Metadata (type of data) a) Viral genome databases, WHO outbreak data; b) C2i’s organoid
datasets, clinical trial data

Data availability a) Publicly available; b) Privately available
Model training Working on: Pre-training of hybrid BioNeMo + DeepSeekMoE archi-
tecture (using ESM-2/Geneformer backbones) on federated biological
datasets.
Current Focus: Domain-specific fine-tuning for drug discovery work-
flows (target: **>93% accuracy** by end-Nov).
Testbeds or pilot 2 biotech partners testing protein function prediction in Hong Kong
deployments and Shanghai
2 hospital labs validating gene expression analysis in Hong Kong
Initial Metrics: Latency <80ms, user satisfaction > 4.7/5

142